Abstract: The present invention relates to a technological platform for the delivery of lipophilic active ingredients.

Abstract: The present application discloses a composition for the treatment of Painful Damaged Disc Syndrome (PDDS), disc bulge, protrusion and herniation, and a delivery method and recommended treatment protocol for delivering thereto to a subject with an effective dosage of the composition. The composition has anti-inflammatory, antioxidant and vasodilating and antispasmodic properties. The compound is being administered via intravenous drip over a specified period for pain relief.

Abstract: Compositions and methods for wound treatment. Compositions may be formulated as a dry powder. Compositions may include an antibiotic and a metal-containing species. Each of the antibiotic and the metal-containing species may positively modulate wound bed and peri-lesional cellular processes supportive of healing. Methods may include a two-step protocol. The first protocol step may be spreading upon a wound surface an emollient-rich mixture of low-and high-molecular weight (MW) non-water-soluble ingredients of an anti-microbial ointment, forming an occlusive cover over the wound. The second protocol step may be to apply the compositions onto the cover. Low-MW emollients may migrate into, and solubilize components of, the dry powder. The solubilized components and the low-MW emollients may transport below the cover to the wound bed to facilitate effective wound healing. Initial testing and use studies have yielded good wound closures, with minimal-to-no scarring and high regain of function of repaired tissues.

Abstract: A topical preparation for use in treating dermatological ailments is prepared from a mixture comprising salicylic acid or a salt thereof, zinc or a salt thereof, iodine or a salt thereof, and a pharmaceutically acceptable carrier vehicle. The preparation comprises any one or more of anti-inflammatory properties, keratolytic properties, anti-pruritic properties, anti-carcinogenic properties. Methods of treatment involving topical application of the preparation are also described.

Abstract: Provided is a cosmetic composition that includes: (a) at least one surfactant, which includes at least one anionic surfactant; and (b) a fatty acid thickener. The cosmetic composition may be transparent and sulfate free.

Abstract: A method of enhancing the quality of a skin scar by topical application of an agent for improving scar quality is characterised in that said agent is pre-emptively applied to a potential surgical cutaneous site in advance of surgery, including surgery involving use of lasers. The topical agent may be a polyphenol, such as (-)-epigallocatechin-3-gallate (EGCG). Use of such a topical agent in advance of surgery leads to significant beneficial effects on dermal scarring by reducing mast cells, angiogenesis, skin thickness and simultaneously increasing elastin content. The topical agent may be applied directly or incorporated in a dressing, such as in a dermal patch comprising an adhesive silicone sheet, and can be worn both in the lead up to surgery and post-operatively.

Abstract: A liquid-holding edible gummy or edible chew for oral consumption by an individual is disclosed. The gummy is a novel, cost-effective, hollow edible that enables users to consume a desired liquid such as an alcohol shot, a medicine, and more without using conventional bottles, cans, and more. The gummy includes a housing made of a gelling substance and the housing encloses a central cavity which holds a liquid. When the gummy is bitten or chewed, the liquid comes out from the cavity and provides a unique way of consuming the liquid. The gummy can be used as a delivery device for alcohol, medicine, non-alcoholic beverages, etc. The gummy is formed using a mold and the liquid, for example, can be injected inside the cavity through the housing.

Abstract: Provided herein are methods and compositions for modulating a microorganism's response to an antimicrobial agent. In one embodiment, the method comprises contacting the microorganism with an antimicrobial agent and bicarbonate. In one embodiment, provided herein are methods for treating a microbial infection comprising administering to a subject in need an effective amount of (i) bicarbonate and (ii) an antimicrobial agent. Also provided herein are methods of screening for antimicrobial compounds.

Abstract: Provided are a pharmaceutical composition for preventing or treating a coronavirus infection or infectious disease, a composition for disinfection, and a health functional food or feed composition, all including nano-sized graphene oxide, and a method of using the same. Since the nano-sized graphene oxide or a complex thereof has anti-coronavirus activity, the graphene oxide may be used for prevention or treatment of a coronavirus infection, or disinfection of coronaviruses.

Abstract: Antimicrobial azo compounds include azobenzene monomers having a phenyl ring comprising a hydroxyl substituent group. The azobenzene monomers can be reacted with a polymeric material to form an antimicrobial coating that prevents growth of persistent biofilms. In some implementations, the azobenzene monomers can be used to coat the surface of a dental resin-based composite to prevent the formation secondary caries. In some implementations, the azobenzene coating can be used to disperse microbial biofilms through a photofluidization process (rapid photoisomerization) in addition to biochemically preventing formation of the microbial biofilm.

Abstract: Compositions comprising starch-acrylic polymers combined with elemental iodine are disclosed. The SAP-I compositions release non-toxic amounts of iodophor iodine in a sustained, controlled manner. Methods of formation and use of the compositions along with methods of creation and use of devices incorporating the compositions in a variety of healthcare and non-healthcare settings are set forth in detail herein.

Abstract: The present application relates to a novel and efficient process with high yield for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate of the formula (I) in the crystalline form of modification I, wherein the x-ray diffractogram of the compound of the formula (I) in modification exhibits peak maxima of the 2 theta angle at 5.9, 6.9, 22.7, in very high purity which is significantly more cost-effective than the process known from the art and can be performed in customary pilot- and production plant-equipment (stirred tank/devices for isolation).

Abstract: An object of the present invention is to provide a novel use of fermented papaya preparation. A composition of the present invention is a composition for elongating telomeres comprising fermented papaya preparation as an active ingredient.

Abstract: The present technology provides regenerative treatment methods and apparatus to promote regeneration of target biological tissue. Regenerative treatments include the subcutaneous and cutaneous application of carbon dioxide. Regenerative treatment methods include an initial treatment phase and a maintenance treatment phase. Regenerative treatment apparatus include effervescent mineral compositions for cutaneous application of carbon dioxide.

Abstract: A method of reducing the virulence of microbes in or on the human body and a method of sanitizing or disinfecting a surface, area, object, or porous or non porous material is provided. The methods comprise applying or injecting a solution having an effective amount of a conjugated diene for substantially reducing the virulence of the microbes or sanitizing or disinfecting a surface, area, object, or porous or non porous material.

Abstract: The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.

Abstract: The present invention relates to novel heteroaryl-triazole compounds of the general formula (I), in which the structural elements X, R1, R2, R3 and R4 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.

Abstract: A microemulsion composition containing: (A) a polyether-modified organopolysiloxane shown in the following general formula (1) having an HLB of 8.0 or more calculated by Griffin's method; (B) a polyether-modified organopolysiloxane shown in the following general formula (7) having an HLB of 5.0 or less calculated by Griffin's method; (C) a glycerol derivative shown in the following general formula (8); (D) a polyhydric alcohol other than the (C); (E) a silicone oil having a kinematic viscosity of 20 mm2/s or less at 25° C.; and (F) water, where a ratio (A)/(B) of a mass of the (A) to a mass of the (B) satisfies 1.0 to 15.0 and the microemulsion composition has a transparent to translucent appearance at 25° C. This provides a microemulsion composition having a transparent to translucent appearance.

Abstract: Disclosed in the present invention are a preparation method for and a use method of a collagen microfiber hemostatic material. Collagen microfibers are obtained by performing high-speed shearing on a solid collagen material; after the collagen microfibers are dispersed in an aqueous phase, a procoagulant active ingredient modifies the surfaces of the collagen microfibers by means of linking molecules; and a collagen microfiber hemostatic material is obtained by performing high-speed shearing again after freeze drying. The collagen microfiber material can be prepared simply and efficiently by means of high-speed shearing; the biological activity of the collagen material is maintained as much as possible; and the microfibers have a length range of 10-1000 ?m and high dispersibility, thus facilitating spray processing.

Abstract: A wound healing composition is provided that includes a tissue adhesive or epithelial tissue healing agent and metal-modified cerium oxide nanoparticles (mCNPs). The nCNPs have a predominant 3+ surface charge and are in a range of about 3-35 nanometers (nm) in size and mixed in an amount that is in a range of about 0.01 to 0.1 weight percentage of a mixture having the tissue adhesive or epithelial tissue healing agent and the mCNPs. The metal (m) is a stable metallic metal with antimicrobial properties and non-ionizing. The mCNPs includes AgCNP2. A method is provided that uses the healing composition to treat a wound or epithelial tissue. The composition can be used to treat the skin or eye and/or subcutaneous tissue.